Pharmacovigilance in Switzerland
How is it with drug safety system in European country? Follow our guide and you will be in the picture.
And of course, if you feel you need a local consultant, we’re here for you.
Current status of our Swiss pharmacovigilance services:
LCPPV / QPPV in Switzerland
AVAILABLE
Easily managed through Tepsivo Platform >
Local Literature Screening
AVAILABLE
Automated monitoring with Tepsivo Literature >
Who is the main PV authority in Switzerland?
Other important institutions & industry groups
Some of the most important laws
Essential EU Legislation and EMA Guidlines
Switzerland is neither a member of the European Economic Area (EEA) or the EU itself, though it is a member of single market, meaning it does not have to follow pharmacovigilance legislation and guidelines by EMA (European Medicine Organization) exactly as other EU members but, in reality it does anyway.
To navigate through the European regulations, its is useful to know following:
EMA Pharmacovigilance System Manual
Directive 2001/83/EC and Regulation (EC) 726/2004
Commission Implementing Regulation (EU) 520/2012
Local pharmacovigilance specifics
Useful abbreviations & terms to know
If you want to study local materials about pharmacovigilance in Switzerland, following terms will be helpful for you to get familiar with:
EMA (European Medicine Organization)
→ Key part of the EU, dedicated to ensuring the safety and effectiveness of medicines.
ElViS portal (Electronic Vigilance System)
→ Pharmaceutical companies and healthcare professionals can report suspected adverse drug reactions directly via ElViS.
AIPS (Medicinal product information search platform)
→ Search platform with information for authorised human medicines.
VV (Verwaltungsverordnung) & WL (Wegleitung)
→ The published “Administrative Ordinances” (VV) are being replaced by “Guidance documents” (WL) – this relates to the Guidance documents.
UAW (Unerwünschten Arzneimittelwirkungen)
→ ADR / adverse drug reaction
Is LCPPV needed or is EU QPPV enough?
How can be adverse events reported in Switzerland?
Reports can be submitted directly to Swissmedic via their online reporting platform, there are different forms for patients and health professionals.
Pharmaceutical companies and healthcare professionals are encouradge to reported electronically via the online ElViS.
Local medical journals to screen
Here are few examples of Swiss local literature that medical authorization holders should monitor:
SWISS MEDICAL WEEKLY
The official scientific publication of several Swiss medical societies, including the Swiss Society of General Internal Medicine.
It publishes original and review articles across all fields of medicine.
ISSN: 1424-3997
SWISSMEDIC JOURNAL
The official periodical of the Swiss Agency for Therapeutic Products, published in German and French.
It covers topics related to therapeutic products, including legal regulations, risks, and announcements about medicinal products.
ISSN: 2234-9456
REVUE MÉDICALE SUISSE
A prominent medical journal that publishes articles in French, it covers a wide range of medical topics, including clinical research and reviews.
ISSN: 1660-9379
Rather then spending your budget for hours of repetitive manual work to monitor those sources, we recommend to simply automate this task using our Tepsivo Literature solution.
Other interesting resources
SWISSMEDICAL ANNUAL REPORT
It provides a detailed overview of its activities, including statistics on drug approvals, clinical trials, and adverse drug reactions reported.
Scientific publications regarding pharmacovigilance
Did you know that while systemic drugs can have local effects on the eye, ophthalmology has one of the lowest reported rates of adverse drug reactions (ADRs)? This article dives into a fascinating study that aims to quantify these ADRs in Switzerland.
This article dives into the world of drug-induced liver injury (DILI) in Switzerland, using real-world data from the global pharmacovigilance database VigiBase™ to uncover critical insights. With a special focus on the emerging class of checkpoint inhibitors.
Do you need some help with putting the Swiss PV System together? We’re here for you.
And while you’re here…
…consider also our global end-to-end PV solution!
Thanks to the Tepsivo platform, you can get a full pharmacovigilance system in all countries you need – for a fraction of the usual budget.
Tepsivo Oy | Urho Kekkosen katu, 4-6 E, 00 100, Helsinki, Finland | VAT number FI31367614 | contact@tepsivo.com | +358 402 204 698 | Privacy policy














